retatrutide phase 2 trial weight loss diabetes 2024 ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial

GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies. One found that GLP-1 RA users had a

29.36

★★★★☆4.6 (92)

GLP-1s and Hormone Therapy: A Game-Changing Duo for Menopause Belly Fat

27.92

★★★★★4.8 (102)

Medicare will cover GLP-1 drugs for weight loss starting on July 1. Obesity is a known risk factor for at least 13 cancer types, and early research shows GLP-1s may help lower

22.73

★★★★★4.3 (166)

GLP-1RA meds are transforming obesity & diabetes care but do they affect cancer risk? This study found GLP-1RAs may actually reduce the incidence of certain cancers such as cancers of liver or

22.67

★★★★★4.3 (80)

Let's talk about GLP-1 medications in the context of perimenopause and menopause, because this is where the conversation most often gets flattened into something it is not. This is not about vanity,

29.13

★★★★★4.8 (130)

GLP-1 Patches: What They Are and What You Should Know

22.29

★★★★★4.9 (296)

GLP-1 Medications and Menopause Weight Gain: What You Need to Know

21.40

★★★★★4.7 (58)